BRISBANE, Calif., Sept. 23, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that it has appointed Sunil Patel to vice president, Corporate Development and Marketing, and Adrienne Weil to the position of Legal Counsel.

``We are very pleased to have Sunil and Adrienne join the executive team at BiPar,'' stated Hoyoung Huh, M.D., Ph.D., BiPar's president and chief executive officer. ``Sunil's and Adrienne's extensive experience will be a strong asset for BiPar as we anticipate Phase II results from our lead drug candidate, BSI-201, for patients with triple negative breast cancer, and move further toward the commercialization of our cancer therapies.''

Sunil Patel

Sunil Patel will be responsible for all corporate development and marketing activities at BiPar. Patel brings over 15 years of biopharmaceutical experience. He joins BiPar after serving as vice president of Corporate Development at Allos Therapeutics, Inc., where he lead all partnering, in-licensing and merger and acquisition activities for the oncology company. Prior to Allos, Patel held various corporate development, marketing and strategic roles at Connetics, Corp., Abgenix, Inc., Gilead Sciences, Inc. and McKinsey & Company.

Adrienne Weil

Adrienne Weil will oversee all of BiPar's legal activities including the development of legal strategies to protect BiPar's intellectual property, as well as facilitate all aspects of deal making. Weil spent close to two decades at the law offices of Orrick, Herrington & Sutcliffe LLP in San Francisco where she garnered extensive experience in finance, technology and various corporate transactions. She has relevant and broad expertise with all aspects of financing and multiparty agreements, from initial conception to final market delivery.

About BiPar Sciences

BiPar Sciences, Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to meet the significant unmet needs of cancer patients. The company's lead product candidate is BSI-201, which is now in Phase II testing for triple negative breast cancer, ovarian cancer and other malignancies. BSI-201 is a poly (ADP-ribose) polymerase (PARP) inhibitor. The company also is conducting preclinical studies on two additional compounds, BSI-401 (PARP inhibitor) and BSI-301 (anti-tubulin program). BiPar Sciences is privately held with headquarters in Brisbane, California.

          Continuum Health Communications
          Stephanie Ashe
          650.728.7087
          stephanie@continuumhealthcare.com